Akero Total Current Liabilities from 2010 to 2024
| AKRO Stock | USD 19.48 1.02 4.98% |
Total Current Liabilities | First Reported 2017-12-31 | Previous Quarter 19.1 M | Current Value 30.3 M | Quarterly Volatility 9.4 M |
Check Akero Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Akero main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 3.3 M or Selling General Administrative of 29 K, as well as many exotic indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.49. Akero financial statements analysis is a perfect complement when working with Akero Therapeutics Valuation or Volatility modules.
Akero | Total Current Liabilities |
Latest Akero Therapeutics' Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Akero Therapeutics over the last few years. Total Current Liabilities is an item on Akero Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Akero Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Akero Therapeutics' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Akero Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Akero Total Current Liabilities Regression Statistics
| Arithmetic Mean | 6,921,717 | |
| Geometric Mean | 1,431,062 | |
| Coefficient Of Variation | 128.13 | |
| Mean Deviation | 7,756,994 | |
| Median | 222,000 | |
| Standard Deviation | 8,869,121 | |
| Sample Variance | 78.7T | |
| Range | 24.9M | |
| R-Value | 0.83 | |
| Mean Square Error | 26T | |
| R-Squared | 0.69 | |
| Significance | 0.0001 | |
| Slope | 1,650,405 | |
| Total Sum of Squares | 1101.3T |
Akero Total Current Liabilities History
About Akero Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Akero Therapeutics income statement, its balance sheet, and the statement of cash flows. Akero Therapeutics investors use historical funamental indicators, such as Akero Therapeutics's Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Akero Therapeutics investors may use each financial statement separately, they are all related. The changes in Akero Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Akero Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Akero Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Akero Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 19.1 M | 13.9 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Akero Therapeutics Correlation against competitors. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for Akero Stock analysis
When running Akero Therapeutics' price analysis, check to measure Akero Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akero Therapeutics is operating at the current time. Most of Akero Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akero Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akero Therapeutics' price. Additionally, you may evaluate how the addition of Akero Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |
Is Akero Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.24) | Return On Assets (0.20) | Return On Equity (0.31) |
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.